Ongoing clinical trials are currently exploring PARP inhibition in patients with CCA and IDH 1/2 mutation (SOLID trial NCT03991832 or NCT03212274), as outlined in Table 14. The gene discussed is IDH2; the disease is cholangiocarcinoma.